June 23, 2019
ANAHEIM, California — New prostate cancer research shows that adding an interim scan during therapy can help guide a patient’s treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care.
In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatment. While interim PET scans have shown high predictive value for lymphoma patients, this concept has not been previously explored in prostate cancer patients undergoing 177Lu-PSMA therapy.
The retrospective analysis was conducted at Klinikum rechts der Isar hospital, Technical University Munich, Germany including patients who underwent gallium-68 (68Ga)-PSMA11 PET/CT at baseline and after two cycles of 177Lu-PSMA RLT under a compassionate use program.
Instead of standardized uptake value, which is the parameter generally used in such analyses, researchers used qPSMA, an in-house developed software, to evaluate the whole-body tumor burden. “Tumor response was assessed by the changes in PSMA-avid tumor volume from baseline to the second PSMA PET using three classification methods,” explained Andrei Gafita, MD. “Subsequently, we found that tumor response assessed on interim PSMA PET after two RLT cycles was associated with overall survival.”
Gafita stated, “Our results therefore show that interim PSMA PET can be used for therapeutic response assessment in patients undergoing 177Lu-PSMA RLT. Furthermore, occurrence of new lesions in PSMA PET is a prognostic factor for disease progression and could be included in defining tumor response based on PSMA PET imaging.”
“While further analyses involving clinical parameters are warranted,” Gafita adds, “this analysis paves the way for use of interim PSMA PET in a prospective setting during 177Lu-PSMA radioligand therapy.”
Figure: 68Ga-PSMA11 PET MIP images at baseline and after 2 cycles of 177Lu-PSMA radioligand therapy in a patients with mCRPC. Image Credit: Andrei Gafita, Matthias Eiber, TUM School of Medicine, Klinikum rechts der Isar, Munich, Germany.
Abstract 73: “Predictive Value of Interim PSMA PET During 177Lu-PSMA Radioligand Therapy for Overall Survival in Patients with Advanced Prostate Cancer,” Andrei Gafita, Wolfgang Weber, Robert Tauber, and Matthias Eiber, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. SNMMI’s 66th Annual Meeting, June 22-25, Anaheim, CA.
To schedule an interview with the researchers, please contact David Harrison at (410) 804-1728 or email@example.com. All 2019 SNMMI Annual Meeting abstracts can be found online at http://jnm.snmjournals.org/content/60/supplement_1.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.